101 related articles for article (PubMed ID: 35953502)
21. COVID-19 vaccine waning and effectiveness and side-effects of boosters: a prospective community study from the ZOE COVID Study.
Menni C; May A; Polidori L; Louca P; Wolf J; Capdevila J; Hu C; Ourselin S; Steves CJ; Valdes AM; Spector TD
Lancet Infect Dis; 2022 Jul; 22(7):1002-1010. PubMed ID: 35405090
[TBL] [Abstract][Full Text] [Related]
22. Urban monitoring, evaluation and application of COVID-19 listed vaccine effectiveness: a health code blockchain study.
Wang T; Li C; Li H; Li Z
BMJ Open; 2022 Jul; 12(7):e057281. PubMed ID: 35831042
[TBL] [Abstract][Full Text] [Related]
23. Myocarditis and Pericarditis following COVID-19 Vaccination: Inequalities in Age and Vaccine Types.
Li M; Yuan J; Lv G; Brown J; Jiang X; Lu ZK
J Pers Med; 2021 Oct; 11(11):. PubMed ID: 34834458
[TBL] [Abstract][Full Text] [Related]
24. Effectiveness of mRNA vaccines and waning of protection against SARS-CoV-2 infection and severe covid-19 during predominant circulation of the delta variant in Italy: retrospective cohort study.
Fabiani M; Puopolo M; Morciano C; Spuri M; Spila Alegiani S; Filia A; D'Ancona F; Del Manso M; Riccardo F; Tallon M; Proietti V; Sacco C; Massari M; Da Cas R; Mateo-Urdiales A; Siddu A; Battilomo S; Bella A; Palamara AT; Popoli P; Brusaferro S; Rezza G; Menniti Ippolito F; Pezzotti P;
BMJ; 2022 Feb; 376():e069052. PubMed ID: 35144968
[TBL] [Abstract][Full Text] [Related]
25. Severe Acute Myocarditis after the Third (Booster) Dose of mRNA COVID-19 Vaccination.
Mengesha B; Asenov AG; Hirsh-Raccah B; Amir O; Pappo O; Asleh R
Vaccines (Basel); 2022 Apr; 10(4):. PubMed ID: 35455324
[TBL] [Abstract][Full Text] [Related]
26. COVID-19 Mortality and Vaccine Coverage - Hong Kong Special Administrative Region, China, January 6, 2022-March 21, 2022.
Smith DJ; Hakim AJ; Leung GM; Xu W; Schluter WW; Novak RT; Marston B; Hersh BS
MMWR Morb Mortal Wkly Rep; 2022 Apr; 71(15):545-548. PubMed ID: 35421076
[TBL] [Abstract][Full Text] [Related]
27. Use of COVID-19 Vaccines After Reports of Adverse Events Among Adult Recipients of Janssen (Johnson & Johnson) and mRNA COVID-19 Vaccines (Pfizer-BioNTech and Moderna): Update from the Advisory Committee on Immunization Practices - United States, July 2021.
Rosenblum HG; Hadler SC; Moulia D; Shimabukuro TT; Su JR; Tepper NK; Ess KC; Woo EJ; Mba-Jonas A; Alimchandani M; Nair N; Klein NP; Hanson KE; Markowitz LE; Wharton M; McNally VV; Romero JR; Talbot HK; Lee GM; Daley MF; Mbaeyi SA; Oliver SE
MMWR Morb Mortal Wkly Rep; 2021 Aug; 70(32):1094-1099. PubMed ID: 34383735
[TBL] [Abstract][Full Text] [Related]
28. Guidance for Implementing COVID-19 Prevention Strategies in the Context of Varying Community Transmission Levels and Vaccination Coverage.
Christie A; Brooks JT; Hicks LA; Sauber-Schatz EK; Yoder JS; Honein MA;
MMWR Morb Mortal Wkly Rep; 2021 Jul; 70(30):1044-1047. PubMed ID: 34324480
[TBL] [Abstract][Full Text] [Related]
29. Vaccine efficacy against severe COVID-19 in relation to delta variant (B.1.617.2) and time since second dose in patients in Scotland (REACT-SCOT): a case-control study.
McKeigue PM; McAllister DA; Hutchinson SJ; Robertson C; Stockton D; Colhoun HM
Lancet Respir Med; 2022 Jun; 10(6):566-572. PubMed ID: 35227416
[TBL] [Abstract][Full Text] [Related]
30. COVID-19 vaccine effectiveness against symptomatic SARS-CoV-2 infection and severe COVID-19 outcomes from Delta AY.4.2: Cohort and test-negative study of 5.4 million individuals in Scotland.
Kerr S; Vasileiou E; Robertson C; Sheikh A
J Glob Health; 2022 Jul; 12():05025. PubMed ID: 35802764
[TBL] [Abstract][Full Text] [Related]
31. Assessing real-world vaccine effectiveness against severe forms of SARS-CoV-2 infection: an observational study from routine surveillance data in Switzerland.
Anderegg N; Althaus CL; Colin S; Hauser A; Laube A; Mäusezahl M; Wagner M; Zaffora B; Riou J
Swiss Med Wkly; 2022 Apr; 152():w30163. PubMed ID: 35752951
[TBL] [Abstract][Full Text] [Related]
32. Surveillance for Adverse Events After COVID-19 mRNA Vaccination.
Klein NP; Lewis N; Goddard K; Fireman B; Zerbo O; Hanson KE; Donahue JG; Kharbanda EO; Naleway A; Nelson JC; Xu S; Yih WK; Glanz JM; Williams JTB; Hambidge SJ; Lewin BJ; Shimabukuro TT; DeStefano F; Weintraub ES
JAMA; 2021 Oct; 326(14):1390-1399. PubMed ID: 34477808
[TBL] [Abstract][Full Text] [Related]
33. Variation in the COVID-19 infection-fatality ratio by age, time, and geography during the pre-vaccine era: a systematic analysis.
COVID-19 Forecasting Team
Lancet; 2022 Apr; 399(10334):1469-1488. PubMed ID: 35219376
[TBL] [Abstract][Full Text] [Related]
34. COVID-19 Cases and Hospitalizations by COVID-19 Vaccination Status and Previous COVID-19 Diagnosis - California and New York, May-November 2021.
León TM; Dorabawila V; Nelson L; Lutterloh E; Bauer UE; Backenson B; Bassett MT; Henry H; Bregman B; Midgley CM; Myers JF; Plumb ID; Reese HE; Zhao R; Briggs-Hagen M; Hoefer D; Watt JP; Silk BJ; Jain S; Rosenberg ES
MMWR Morb Mortal Wkly Rep; 2022 Jan; 71(4):125-131. PubMed ID: 35085222
[TBL] [Abstract][Full Text] [Related]
35. A Cost-Effectiveness Evaluation of Hospitalizations, Fatalities, and Economic Outcomes Associated with Universal Versus Anaphylaxis Risk-Stratified COVID-19 Vaccination Strategies.
Shaker M; Abrams EM; Greenhawt M
J Allergy Clin Immunol Pract; 2021 Jul; 9(7):2658-2668.e3. PubMed ID: 33711496
[TBL] [Abstract][Full Text] [Related]
36. Effectiveness and impact of the 4CMenB vaccine against invasive serogroup B meningococcal disease and gonorrhoea in an infant, child, and adolescent programme: an observational cohort and case-control study.
Wang B; Giles L; Andraweera P; McMillan M; Almond S; Beazley R; Mitchell J; Lally N; Ahoure M; Denehy E; Koehler A; Flood L; Marshall H
Lancet Infect Dis; 2022 Jul; 22(7):1011-1020. PubMed ID: 35427492
[TBL] [Abstract][Full Text] [Related]
37. COVID-19 Vaccine-Related Myocarditis: A Descriptive Study of 40 Case Reports.
Chen JH; Ikwuanusi IA; Bommu VJL; Patel V; Aujla H; Kaushik V; Cheriyath P
Cureus; 2022 Jan; 14(1):e21740. PubMed ID: 35251812
[TBL] [Abstract][Full Text] [Related]
38. Effectiveness of homologous and heterologous booster doses for an inactivated SARS-CoV-2 vaccine: a large-scale prospective cohort study.
Jara A; Undurraga EA; Zubizarreta JR; González C; Pizarro A; Acevedo J; Leo K; Paredes F; Bralic T; Vergara V; Mosso M; Leon F; Parot I; Leighton P; Suárez P; Rios JC; García-Escorza H; Araos R
Lancet Glob Health; 2022 Jun; 10(6):e798-e806. PubMed ID: 35472300
[TBL] [Abstract][Full Text] [Related]
39. Cardiac Complications After SARS-CoV-2 Infection and mRNA COVID-19 Vaccination - PCORnet, United States, January 2021-January 2022.
Block JP; Boehmer TK; Forrest CB; Carton TW; Lee GM; Ajani UA; Christakis DA; Cowell LG; Draper C; Ghildayal N; Harris AM; Kappelman MD; Ko JY; Mayer KH; Nagavedu K; Oster ME; Paranjape A; Puro J; Ritchey MD; Shay DK; Thacker D; Gundlapalli AV
MMWR Morb Mortal Wkly Rep; 2022 Apr; 71(14):517-523. PubMed ID: 35389977
[TBL] [Abstract][Full Text] [Related]
40. BNT162b2 Vaccine-Associated Myo/Pericarditis in Adolescents: A Stratified Risk-Benefit Analysis.
Krug A; Stevenson J; Høeg TB
Eur J Clin Invest; 2022 May; 52(5):e13759. PubMed ID: 35156705
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
